As an emerging leader in 503B compounding outsourcing, QuVa Pharma has responded to market demands with increased capability and capacity. Its cGMP ability to produce sterile-to-sterile and API-to-sterile products increases available, safe options for health care providers during times of chronic shortages. QuVa Pharma now has three FDA-registered 503B sterile compounding facilities (two in Texas
and one in New Jersey), and an anticipated 90,000 square-feet of additional space as of Q4 2018.
- In The Loop!
- Digital Edition
- Special Announcements